Compare Abeona Therapeutics Inc (ABEO) vs OneSpan Inc (OSPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs OneSpan Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while OneSpan Inc trades at $14.75 (market cap $559.43M). The key difference: OneSpan Inc is the larger of the two by market cap, and OneSpan Inc pays a 3.45% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | OSPN | |
|---|---|---|
Market Cap | $373.32M | $559.43M |
Sector | Health | Technology |
52-Week High | $7.23 | $18.05 |
52-Week Low | $4.17 | $10.15 |
Enterprise Value | $228.22M | $517.63M |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
OneSpan (OSPN) trades at $15.09, up 4.5% today, showing strong momentum despite trading above the analyst consensus price target of $13.50. The stock exhibits bullish technical signals with recent earnings beats and robust profitability metrics including 28.5% net income margin and 27.8% ROE. Recent corporate developments include leadership team expansion and digital credentials launch, signaling growth initiatives.
The outlook remains positive with strong analyst support (67% buy ratings) and attractive valuation multiples (P/E 8.3x), though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains earnings momentum, while execution risks and market volatility present headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
